Earnings Call · Q2 FY2024·2024-08-09

Q2 24EPS -8.18%·Rev n/aQ1 24EPS -32.32%·Rev n/aQ4 23EPS +11.81%·Rev n/aQ3 23EPS -4.00%·Rev n/a⚠ consensus missing

INOVIO PHARMACEUTICALS, INC. INO

Thomas Hong — Host/Investor Relations

Jacqueline Shea — President and Chief Executive Officer

Steve Egge — Chief Commercial Officer

Michael Sumner — Chief Medical Officer

Peter Kies — Chief Financial Officer

+1.4%1d on move date−0.9% vs SPY3d−3.1%5d−9.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INO calls or request research access.

More INO calls Browse calls Request research access